Date: 2011-01-28
Type of information: Development agreement
Compound: house dust mite allergy immunotherapy products (Mitizak®, Alutard®)
Company: ALK (Denmark)Torii Pharmaceutical Co (Japan)
Therapeutic area: Respiratory diseases - Inflammatory diseases - Allergic diseases
Type agreement: development
commercialisation
Action mechanism: immunotherapy products
Disease: asthma - allergic rhinitis
Details: ALK and Torii Pharmaceutical have entered into an exclusive license agreement to develop and commercialise ALK’s house dust mite allergy immunotherapy products for asthma and allergic rhinitis in Japan. The agreement gives Torii exclusive license rights for the development, marketing and distribution of ALK’s tablet based immunotherapy product against house dust mite allergy – Mitizak®. The agreement also covers an injection based immunotherapy product, Alutard®, and diagnostic products against house dust mite allergy. Moreover, the agreement includes a research and development collaboration targeting a tablet based immunotherapy product against Japanese cedar pollen allergy.
Financial terms: Under the agreement, ALK will receive an upfront payment of € 30 million and up to € 30 million in development and market registration milestone payments. ALK will also receive royalty payments and sales milestones on the net sales of the products. Torii will be incurring all the costs of clinical development, registration, marketing and sale of the products, while ALK will be responsible for production and supply of the products.
Latest news:
